Genetic testing company Natera (NASDAQ: NTRA). will be reporting results this Thursday afternoon. Here’s what investors should know.
Natera beat analysts’ revenue expectations last quarter, reporting revenues of $592.2 million, up 34.7% year on year. It was a very strong quarter for the company, with a solid beat of analysts’ revenue estimates and full-year revenue guidance exceeding analysts’ expectations.
Is Natera a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Natera’s revenue to grow 27.1% year on year, slowing from the 53% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Natera has a history of exceeding Wall Street’s expectations.
Looking at Natera’s peers in the immuno-oncology segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Exact Sciences delivered year-on-year revenue growth of 23.1%, beating analysts’ expectations by 2.1%, and Regeneron reported revenues up 2.5%, topping estimates by 2.7%. Exact Sciences’s stock price was unchanged after the resultsand Regeneron’s price followed a similar reaction.
Read our full analysis of Exact Sciences’s results here and Regeneron’s results here.
Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the immuno-oncology stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.7% on average over the last month. Natera is down 14.5% during the same time and is heading into earnings with an average analyst price target of $257.20 (compared to the current share price of $206.38).
P.S. STOP buying the AI stocks everyone's talking about. The real money? It’s in the profitable pick nobody’s watching yet. We’ve identified an AI profit machine that’s flying under Wall Street’s radar—for now. We can’t keep this research public forever—grab your FREE copy before we pull it offline. GO HERE NOW.
